Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study von Giovannoni, Gavin, Soelberg Sorensen, Per, Cook, Stuart, Rammohan, Kottil, Rieckmann, Peter, Comi, Giancarlo, Dangond, Fernando, Adeniji, Abidemi K, Vermersch, Patrick

Volltext

The Multiple Sclerosis Care Unit von Soelberg Sorensen, Per, Giovannoni, Gavin, Montalban, Xavier, Thalheim, Christoph, Zaratin, Paola, Comi, Giancarlo

Volltext

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study von Sorensen, Per S, Lisby, Steen, Grove, Richard, Derosier, Frederick, Shackelford, Steve, Havrdova, Eva, Drulovic, Jelena, Filippi, Massimo

Volltext

Comorbidity in Multiple Sclerosis von Magyari, Melinda, Sorensen, Per Soelberg

Volltext

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study von Comi, Giancarlo, Cook, Stuart, Rammohan, Kottil, Soelberg Sorensen, Per, Vermersch, Patrick, Adeniji, Abidemi K., Dangond, Fernando, Giovannoni, Gavin

Volltext

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study von Bar-Or, Amit, Grove, Richard A, Austin, Daren J, Tolson, Jerry M, VanMeter, Susan A, Lewis, Eric W, Derosier, Frederick J, Lopez, Monica C, Kavanagh, Sarah T, Miller, Aaron E, Sorensen, Per S

Volltext

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality von Thormann, Anja, Sørensen, Per Soelberg, Koch-Henriksen, Nils, Laursen, Bjarne, Magyari, Melinda

Volltext

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study von Giovannoni, Gavin, Soelberg Sorensen, Per, Cook, Stuart, Rammohan, Kottil W, Rieckmann, Peter, Comi, Giancarlo, Dangond, Fernando, Hicking, Christine, Vermersch, Patrick

Volltext

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview von Marrie, Ruth Ann, Cohen, Jeffrey, Stuve, Olaf, Trojano, Maria, Sørensen, Per Soelberg, Reingold, Stephen, Cutter, Gary, Reider, Nadia

Volltext

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis von Marrie, Ruth Ann, Reider, Nadia, Cohen, Jeffrey, Stuve, Olaf, Sorensen, Per S, Cutter, Gary, Reingold, Stephen C, Trojano, Maria

Volltext

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial von Lopes, Renato D., Higano, Celestia S., Slovin, Susan F., Nelson, Adam J., Bigelow, Robert, Sørensen, Per S., Melloni, Chiara, Goodman, Shaun G., Evans, Christopher P., Nilsson, Jan, Bhatt, Deepak L., Clarke, Noel W., Olesen, Tine K., Doyle-Olsen, Belinda T., Kristensen, Henriette, Arney, Lauren, Roe, Matthew T., Alexander, John H.

Volltext

Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 von Sun, Shaoxiong, Folarin, Amos A, Ranjan, Yatharth, Rashid, Zulqarnain, Conde, Pauline, Stewart, Callum, Cummins, Nicholas, Matcham, Faith, Dalla Costa, Gloria, Simblett, Sara, Leocani, Letizia, Lamers, Femke, Sørensen, Per Soelberg, Buron, Mathias, Zabalza, Ana, Guerrero Pérez, Ana Isabel, Penninx, Brenda Wjh, Siddi, Sara, Haro, Josep Maria, Myin-Germeys, Inez, Rintala, Aki, Wykes, Til, Narayan, Vaibhav A, Comi, Giancarlo, Hotopf, Matthew, Dobson, Richard Jb

Volltext

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study von van den Brink, Wim, Sørensen, Per, Torup, Lars, Mann, Karl, Gual, Antoni

Volltext

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO von Soelberg Sorensen, Per

Volltext

Ozanimod: a better or just another S1P receptor modulator? von Sørensen, Per Soelberg

Volltext

Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy von Mann, Karl, Torup, Lars, Sørensen, Per, Gual, Antoni, Swift, Robert, Walker, Brendan, van den Brink, Wim

Volltext

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial von Romme Christensen, Jeppe, Ratzer, Rikke, Börnsen, Lars, Lyksborg, Mark, Garde, Ellen, Dyrby, Tim B, Siebner, Hartwig R, Sorensen, Per S, Sellebjerg, Finn

Volltext

Assessing disease progression and treatment response in progressive multiple sclerosis von Comi, Giancarlo, Dalla Costa, Gloria, Stankoff, Bruno, Hartung, Hans-Peter, Soelberg Sørensen, Per, Vermersch, Patrick, Leocani, Letizia

Volltext

Defining the clinical course of multiple sclerosis: The 2013 revisions von Lublin, Fred D, Reingold, Stephen C, Cohen, Jeffrey A, Cutter, Gary R, Sørensen, Per Soelberg, Thompson, Alan J, Wolinsky, Jerry S, Balcer, Laura J, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Calabresi, Peter A, Clanet, Michel, Comi, Giancarlo, Fox, Robert J, Freedman, Mark S, Goodman, Andrew D, Inglese, Matilde, Kappos, Ludwig, Kieseier, Bernd C, Lincoln, John A, Lubetzki, Catherine, Miller, Aaron E, Montalban, Xavier, OʼConnor, Paul W, Petkau, John, Pozzilli, Carlo, Rudick, Richard A, Sormani, Maria Pia, Stüve, Olaf, Waubant, Emmanuelle, Polman, Chris H

Volltext

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review von Marrie, Ruth Ann, Reingold, Stephen, Cohen, Jeffrey, Stuve, Olaf, Trojano, Maria, Sorensen, Per Soelberg, Cutter, Gary, Reider, Nadia

Volltext